BR112015014137A2 - unidade sólida com alto teor de fexofenadina e processo para a preparação da mesma - Google Patents

unidade sólida com alto teor de fexofenadina e processo para a preparação da mesma

Info

Publication number
BR112015014137A2
BR112015014137A2 BR112015014137A BR112015014137A BR112015014137A2 BR 112015014137 A2 BR112015014137 A2 BR 112015014137A2 BR 112015014137 A BR112015014137 A BR 112015014137A BR 112015014137 A BR112015014137 A BR 112015014137A BR 112015014137 A2 BR112015014137 A2 BR 112015014137A2
Authority
BR
Brazil
Prior art keywords
fexofenadine
preparing
solid unit
solid
unit
Prior art date
Application number
BR112015014137A
Other languages
English (en)
Other versions
BR112015014137B1 (pt
BR112015014137B8 (pt
Inventor
Merillon Baptiste
Lanne Jean-Yves
Renouard Marie
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47902228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015014137(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112015014137A2 publication Critical patent/BR112015014137A2/pt
Publication of BR112015014137B1 publication Critical patent/BR112015014137B1/pt
Publication of BR112015014137B8 publication Critical patent/BR112015014137B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo patente de invenção: "unidade sólida com alto teor de fexofenadina e processo para a preparação da mesma". a presente invenção refere-se às composições farmacêuticas destinadas a ser usadas na forma de uma unidade sólida tal como um comprimido, para administração oral, compreendendo um alto teor de fexofenadina e/ou de pelo menos um sal da mesma farmaceuticamente aceitável, e também aos processos termo fundidos para a preparação de unidades sólidas.
BR112015014137A 2012-12-21 2013-12-20 Composição com alto teor de fexofenadina e processo para a preparação da mesma BR112015014137B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1262647A FR2999937B1 (fr) 2012-12-21 2012-12-21 Unite solide a haute teneur en fexofenadine et son procede de preparation
FR1262647 2012-12-21
PCT/EP2013/077752 WO2014096387A1 (en) 2012-12-21 2013-12-20 Solid unit with high fexofenadine content and process for the preparation thereof

Publications (3)

Publication Number Publication Date
BR112015014137A2 true BR112015014137A2 (pt) 2017-07-11
BR112015014137B1 BR112015014137B1 (pt) 2022-12-13
BR112015014137B8 BR112015014137B8 (pt) 2023-01-24

Family

ID=47902228

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014137A BR112015014137B8 (pt) 2012-12-21 2013-12-20 Composição com alto teor de fexofenadina e processo para a preparação da mesma

Country Status (25)

Country Link
US (1) US9757340B2 (pt)
EP (1) EP2934491B1 (pt)
JP (1) JP6276287B2 (pt)
KR (1) KR20150100725A (pt)
CN (1) CN105073101B (pt)
AR (1) AR094146A1 (pt)
AU (1) AU2013366512B2 (pt)
BR (1) BR112015014137B8 (pt)
CA (1) CA2895607A1 (pt)
CL (1) CL2015001681A1 (pt)
EA (1) EA030982B1 (pt)
ES (1) ES2625447T3 (pt)
FR (1) FR2999937B1 (pt)
HK (1) HK1211234A1 (pt)
HU (1) HUE032393T2 (pt)
IL (1) IL239267A0 (pt)
MX (1) MX360047B (pt)
PH (1) PH12015501377A1 (pt)
PL (1) PL2934491T3 (pt)
SG (1) SG11201504394TA (pt)
TN (1) TN2015000267A1 (pt)
TW (1) TWI624275B (pt)
UY (1) UY35235A (pt)
WO (1) WO2014096387A1 (pt)
ZA (1) ZA201504079B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2956011T3 (pl) 2013-02-14 2018-09-28 Sanofi Kompozycja do żucia do podawania doustnego i sposób jej wytwarzania
TW201717949A (zh) * 2015-10-29 2017-06-01 日本臟器製藥股份有限公司 以非索非那定為有效成分之錠劑
JP7487290B2 (ja) 2020-03-11 2024-05-20 沢井製薬株式会社 顆粒及びそれを用いた製剤
WO2023145871A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法
WO2023145869A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044319C (zh) * 1984-08-30 1999-07-28 默里尔多药物公司 热熔融抗组胺组合物的制备方法
DK164642C (da) * 1984-08-30 1992-12-14 Merrell Dow Pharma Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
JP4105762B2 (ja) 1995-02-28 2008-06-25 アベンティス・ファーマスーティカルズ・インコーポレイテツド ピペリジノアルカノール化合物のための医薬組成物
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
DE602004010732T2 (de) * 2003-03-07 2008-12-24 Ind-Swift Ltd. Geschmacklose, direkt verpressbare, schnelllösliche Komplexe und ihre pharmazeutischen Zusammensetzungen.
FR2959130A1 (fr) * 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
PL2956011T3 (pl) 2013-02-14 2018-09-28 Sanofi Kompozycja do żucia do podawania doustnego i sposób jej wytwarzania

Also Published As

Publication number Publication date
PL2934491T3 (pl) 2017-09-29
EA201591150A1 (ru) 2015-11-30
CL2015001681A1 (es) 2015-08-21
MX2015008068A (es) 2016-04-25
EA030982B1 (ru) 2018-10-31
BR112015014137B1 (pt) 2022-12-13
HK1211234A1 (en) 2016-05-20
EP2934491A1 (en) 2015-10-28
JP6276287B2 (ja) 2018-02-07
IL239267A0 (en) 2015-07-30
US20150313885A1 (en) 2015-11-05
KR20150100725A (ko) 2015-09-02
ZA201504079B (en) 2016-04-28
FR2999937B1 (fr) 2015-01-09
EP2934491B1 (en) 2017-02-22
UY35235A (es) 2014-07-31
FR2999937A1 (fr) 2014-06-27
US9757340B2 (en) 2017-09-12
MX360047B (es) 2018-10-19
PH12015501377A1 (en) 2015-09-02
TN2015000267A1 (en) 2016-10-03
AU2013366512A1 (en) 2015-07-09
ES2625447T3 (es) 2017-07-19
CN105073101A (zh) 2015-11-18
AR094146A1 (es) 2015-07-15
WO2014096387A1 (en) 2014-06-26
TWI624275B (zh) 2018-05-21
JP2016511223A (ja) 2016-04-14
CA2895607A1 (en) 2014-06-26
SG11201504394TA (en) 2015-07-30
TW201431569A (zh) 2014-08-16
HUE032393T2 (en) 2017-09-28
CN105073101B (zh) 2018-10-09
BR112015014137B8 (pt) 2023-01-24
AU2013366512B2 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
BR112015018168A2 (pt) inibidores de rock suaves
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112015018838A2 (pt) estabilidade melhorada de novas composições líquidas
BR112015007647A2 (pt) derivados de quetamina
BR112015014137A2 (pt) unidade sólida com alto teor de fexofenadina e processo para a preparação da mesma
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112014031091A2 (pt) Derivados de piperidina para agonista de gpr119
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112012028308A2 (pt) formulações oftálmicas de galactomanano estabilizadas
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
BR112013030391A2 (pt) derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina
UA117154C2 (uk) Антагоністи s1p3
BR112015030431A2 (pt) formulação de liberação modificada
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
BR112014004732A2 (pt) composto benzotiazolona
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
BR112014016450A2 (pt) composto antagonista de leucotrieno b4

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2013, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2710 DE 13/12/2022, QUANTO AO ITEM (54) TITULO.